Victrex (OTCMKTS:VTXPF) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a note issued to investors on Sunday.
According to Zacks, “Victrex Plc engages in the manufacture and marketing of polymers. The company offers products under the Victrex, Aptiv, Vicote and Victrex Pipes brands. It operates through the Victrex Polymer Solutions and Invibio Biomaterial Solutions segments. Victrex Polymer Solutions segment focuses on the automotive, aerospace, electronics and energy markets. Invibio Biomaterial Solutions provides solutions for medical device manufacturers. Victrex Plc is headquartered in Thornton Cleveleys, United Kingdom. “
Shares of Victrex (OTCMKTS:VTXPF) opened at $35.95 on Friday. Victrex has a 12 month low of $22.80 and a 12 month high of $37.58.
WARNING: This piece of content was reported by American Banking News and is the property of of American Banking News. If you are accessing this piece of content on another domain, it was copied illegally and reposted in violation of US and international copyright and trademark legislation. The original version of this piece of content can be viewed at https://www.americanbankingnews.com/2018/01/21/victrex-vtxpf-downgraded-by-zacks-investment-research.html.
Victrex plc, through its subsidiaries, manufactures and sells polymers worldwide. It operates through two segments, Victrex Polymer Solutions and Invibio Biomaterial Solutions. The company offers VICTREX PEEK polymer materials; and biomaterial solutions for use in spine, dental, trauma, knee, cardiovascular, and orthopedic applications.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Victrex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Victrex and related companies with MarketBeat.com's FREE daily email newsletter.